Skip to main content
Clinical Trials/DRKS00005742
DRKS00005742
Completed
未知

Post-market clinical follow-up investigation of the marketed Extended Range of Vision IOL (Intraocular lens) - EROV-108-COMP

Abbott Medical Optics Inc.0 sites147 target enrollmentMarch 25, 2014

Overview

Phase
未知
Intervention
Not specified
Conditions
h25
Sponsor
Abbott Medical Optics Inc.
Enrollment
147
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 25, 2014
End Date
October 13, 2015
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • · Minimum 22 years of age
  • · Planned natural lens replacement with posterior chamber IOL implantation
  • · Visual potential of 20/25 or better in the operative eye following natural lens
  • replacement with an IOL
  • · Normal corneal topography
  • · Clear intraocular media other than cataract in each eye
  • · Availability, willingness, sufficient cognitive awareness to comply with examination
  • · Ability to sign informed consent

Exclusion Criteria

  • · Requiring an intraocular lens power outside the available range of \+16\.0 D to
  • · Patients with recurrent severe anterior or posterior segment inflammation or uveitis
  • of unknown etiology, or any disease producing an inflammatory reaction in the eye
  • · Patients in whom the intraocular lens may affect the ability to observe, diagnose or
  • treat posterior segment diseases
  • · Expected surgical difficulties at the time of cataract extraction, which may increase
  • the potential for complications (e.g., persistent bleeding, significant iris damage,
  • uncontrolled positive pressure or significant vitreous prolapse or loss)
  • · A compromised eye due to previous trauma or developmental defects in which
  • appropriate support of the IOL is not possible

Outcomes

Primary Outcomes

Not specified

Similar Trials